Biotech Co. Can't Arbitrate $881M Cannabinoid IP Fight
By Melissa Angell (July 26, 2021, 9:29 PM EDT) -- A New York federal judge on Monday denied biotech company Amyris' bid to arbitrate an $881 million trade secrets fight with cannabinoid manufacturer Lavvan, finding that a prior agreement the parties entered into requires them to litigate intellectual property disputes.
U.S. District Judge J. Paul Oetken ruled in his 11-page decision that Amyris cannot compel arbitration because of a provision found in the research and development agreement the parties executed that "explicitly carves out intellectual property disputes from arbitration."
"The [agreement], in other words, demonstrates that the parties explicitly agreed that intellectual property disputes would be determined by a court," the...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!